



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 22 May 2023 (#18)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.

Important Notices

NOT-HL-23-086 National Heart, Lung, and Blood Institute (NHLBI) TOPMed Announces Fellowship Program to Promote Diversity, Equity, and Inclusion in the Genomic Data Science Research Workforce. The purpose of this Notice is to inform the research community of the release of a program solicitation on May 1, 2023, announcing the availability of a fellowship program opportunity with activities intended to develop a cadre of scientists from diverse backgrounds, including those from underrepresented groups in biomedical research, that will have expertise in the areas of genetics and genomics relevant to heart, lung, blood, and sleep diseases and disorders. The program solicitation was released on the TOPMed Administrative Coordinating Center (ACC) website: [2023 TOPMed Fellowship](#). **Open only to those foreign institutions that have received funds from major NIH initiatives on genomics/data science (e.g., H3Africa and DS-I Africa).** Application Due Date: July 31, 2023, 5:00PM EDT. **Award Budget:** Award budgets are composed of salary supporting trainee's effort between 25% to 100% and travel budget for a trip to the TOPMed annual meeting held in Washington, D.C.'s metro area, as well as an additional trip to a relevant national/international conference if trainee presents poster or oral presentation. The direct cost should not to exceed \$70,000 and the indirect cost will be at 10% of direct cost. **Period of Performance:** The award project period is one year. An informational webinar session will be held for applicants prior to application submission. Slides will be made available on this webpage after the webinar. Date and time: June 5th, 2023, 2:00pm ET Meeting link: <https://westat.zoomgov.com/j/1603168579?pwd=TzM2SzhsOTI5SFIGamNVNlFkdGtqZz09>

- Meeting ID: 160 316 8579
- Passcode: 577928

Parent Announcements

NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates Expiration Date: May 8, 2023 **Modified Key Dates Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

[NOT-AA-23-013](#) **Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in [PAR-23-191](#)** "HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)"

[NOT-OD-23-130](#) **Notice of the Extension of the Expiration Date for [NOT-OD-23-040](#):** "Notice of Special Interest (NOSI): Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21)" *New Expiration Date: January 5, 2024.*

Notice of Special Interest (NOSI)

[NOT-AG-23-027](#) **Small Research Grants for Innovations in Healthy Longevity Research.** This Notice of Special Interest (NOSI) invites applications for small research grants that align with the goals of the National Academy of Medicine's [Healthy Longevity Grand Challenge](#), as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Research programs that include populations considered vulnerable or under-researched (e.g., women, indigenous populations, populations in adverse environmental settings, etc.) in low- and middle-income countries are also encouraged. This notice applies to due dates on or after July 16, 2023 and subsequent receipt dates through May 8, 2024.

[NOT-MH-23-250](#) **Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults.** The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications that include developmentally tailored research focused on adolescents and young adults (youth) related to HIV prevention and treatment. This Notice of Special Interest is a reissue of [NOT-MH-20-035](#). This notice applies to due dates on or after Sept 7, 2023 and subsequent receipt dates through Sept 8, 2026.

Notice of Funding Opportunity (NOFO)

1. Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-029](#)

Type: R01

Application Due Date: **October 11, 2023.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies.

Budget: NIAID intends to commit \$2,000,000 in FY 2024 to fund 3 to 4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-032](#)

Type: U24

Application Due Date: **August 25, 2023.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the Bioinformatics Resource Center (BRC) Program that will (1) create and manage integrated knowledgebases to accelerate basic and applied human infectious diseases research, (2) develop advanced innovative bioinformatics technologies for software and tools, (3) offer state-of-the-art bioinformatics expertise for investigators and (4) respond with cutting-edge bioinformatics in response to emerging needs, outbreaks, and public health emergencies.

Budget: NIAID intends to commit \$9 million in FY2024 to fund 1-2 awards. Direct costs for the applications should be based on the number of Biological Domain(s) proposed. Budgets proposing one biological domain are not expected to exceed \$2,500,000 direct cost per year. Budgets proposing two biological domains are not expected to exceed \$4,800,000 direct per year. Application budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-023](#)

Type: R01

Application Due Date: Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by [World Bank Classification](#)). Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply. Eligibility status of applicant organizations will be determined by the World Bank Classification list at the time of application submission.

Budget: NIAID intends to commit \$1,360,000 in FY 2024 to fund 7-8 awards. Application budgets should not exceed \$125,000 in direct costs per year, and should reflect the actual needs of the project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-23-026](#)

Type: R61/R33

Application Due Date: August 02, 2023 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Notice of Funding Opportunity (NOFO) is to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.

Budget: NIAID intends to commit \$3,000,000 in FY 2024 to fund 3-5 awards. Application budgets are limited to \$500,000 in direct costs per year in the R61 phase and \$750,000 in direct costs per year in the R33 phase. All F&A costs are excluded from this limit. Requested budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for an application submitted in response to this NOFO cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

5. Alcohol Health Services Research (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-185](#)

Type: R01

Application Due Date: July 18, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Companion Funding Opportunity: [PAR-23-186](#) (R34), [PAR-23-187](#) (R01), [PAR-23-188](#), (R34)

Budget: Direct costs may not exceed \$500,000 without prior approval (see Section IV. Application and Submission Information). The maximum project period is five years.

6. Alcohol Treatment and Recovery Research (R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-187](#)

Type: R01

Application Due Date: July 18, 2023 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

Companion Funding Opportunity: [PAR-23-185](#)(R01), [PAR-23-186](#) (R34), [PAR-23-188](#), (R34)

Budget: Direct costs may not exceed \$500,000 without prior approval (see Section IV. Application and Submission Information). The maximum project period is five years.

7. Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-23-193](#)

Type: X01

Application Due Date: October 3, 2023, April 3, 2024, October 3, 2024, April 3, 2025, October 3, 2025, April 3, 2026 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug

(IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding).
Budget: Not Applicable. There are no funds associated with these X01 resource access awards. The maximum project period is one year.

8. Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-021](#)

Type: U01

Application Due Date: October 23, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: This Notice of Funding Opportunity (NOFO) invites applications that propose interdisciplinary research projects that utilize disease relevant human cell-based in vitro and ex vivo models to characterize the effects of gene-environment (GxE) interactions on gene regulation and cellular functions, and to elucidate toxicant mediated molecular and cellular mechanisms in brain aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD). The objective of this initiative is to stimulate research to gain mechanistic insights into GxE interactions in response to environmental toxicants using human cell-based models.

Budget: NIA intends to commit \$3.5 million in fiscal year 2024 to support 5-6 awards. Application budgets need to reflect the actual needs of the proposed project and must be limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-022](#)

Type: U01

Application Due Date: October 23, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: This Notice of Funding Opportunity (NOFO) invites applications that propose research focused on major toxicants observed to be associated with elevated Alzheimer's Disease (AD) and AD-related dementias (ADRD) risk, and health disparities in AD/ADRD-related pathologic and clinical outcomes. This NOFO aims to do the following:

- Enrich existing longitudinal cohorts with measures of exposures to individual toxicants or combinations of toxicants and/or multi-omics molecular profiling that reflects the body's response to exposure(s)
- Support the development of multi-disciplinary teams needed for the rigorous measurement and assessment of environmental exposures at the population level
- Create an environmental epidemiology consortium to facilitate rapid and broad data sharing, harmonization, and integration of complex exposure data across multiple studies to enhance the opportunity for data pooling and data integration for various meta-analyses and/or comparative analyses

Budget: NIA intends to commit \$11 million in fiscal year 2024 to support 4-5 awards. Application budgets are limited to \$1.5 million in direct costs per year over 5 years. Application budgets need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

10. Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-023](#)

Type: U01

Application Due Date: October 23, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to evaluate the molecular, pathologic, and functional consequences of major toxicants known to be associated with elevated Alzheimer's Disease (AD) and AD-related dementias (ADRD) risk by conducting cross-sectional/longitudinal multi-modal (i.e., molecular, biochemical, pathologic and behavioral) phenotyping. The central goal is to examine the consequences of early and mid-life exposure on late life brain health, including the impact of genetic diversity and sex differences on exposure-related AD/ADRD outcomes across brain and peripheral tissues.

Budget: NIA intends to commit \$4 million in fiscal year 2024 to support 2 awards. Application budgets are capped at \$1.25 million in direct costs per year. The requested budget needs to be well justified and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

11. Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-036](#)

Type: R01

Application Due Date: October 23, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this initiative is to develop measures of financial hardship associated with Alzheimer's disease (AD) and AD-related dementias (ADRD) that are responsive to the dyadic and family-level financial management arrangements that are common as AD/ADRD progresses. In order to accurately measure financial hardship among people and families living with AD/ADRD, validated screeners are needed to capture unique hardships associated with AD/ADRD that are not measured in screeners developed for people with cancer or in screeners developed for healthy households. This notice of funding opportunity (NOFO) invites research to support the development of measures of

financial hardship for persons living with AD/ADRD and their partners, families, or caregivers to facilitate research on financial health – a key social determinant of health – and health- related quality of life among older adults with AD/ADRD.

Budget: NIA intends to commit \$3,000,000 in fiscal year 2024 to fund 6 awards. Applications budgets are limited to \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

12. Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-038](#)

Type: R01

Application Due Date: October 23, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate the use of existing biospecimens and datasets (i.e., secondary analysis) which will increase our understanding of the clinical significance of clonal hematopoiesis (CH) mutations, their causality, directionality, relationships with different human aging phenotypes, and underlying biological mechanisms. CH is a condition related to aging wherein clonal expansion of hematopoietic cells driven by somatic mutations increases markedly with age in humans. While associations of CH with higher risk for age-related cardiovascular disease have been reported, an in-depth understanding of the interplay of CH mutations, aging, and physiological/clinical outcomes is needed for potential risk stratification for other age-related diseases, therapeutic target identification, and development of therapeutic interventions to promote healthy aging. In this regard, virtually little is known about the relationship between CH mutations and exceptionally healthy aging phenotypes. This NOFO will use the R01 grant mechanism to support studies using sequencing-based analyses of biospecimens from epidemiological cohorts with extensive physiologic, genetic, and omics data to assess the clinical significance of somatic mutations for a variety of age-related outcomes. New data and specimen collection (e.g., follow-up of individuals for additional phenotypic characterization and biospecimen collection, generation of sequencing data) to supplement existing datasets is allowed when essential for addressing the specific aims of the proposed study. Studies should consider both potential deleterious and protective effects of CH mutations and the molecular mechanisms underpinning pleiotropic effects of CH in aging. Analysis of biospecimens from clinical trials focused on age-related outcomes is also strongly encouraged to assess and clarify the relationship of CH to treatment effects and to evaluate the clinical utility of CH screening in clinical practice for risk prediction and prognosis for age-related disease.

Budget: NIA intends to commit \$5 million in fiscal year 2024 to fund up to 4 applications, contingent on funding availability. Application budgets are limited to up to \$1 million in direct costs, and the requested budget should reflect the actual needs of the proposed R01 project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

13. Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-024](#)

Type: R61/R33

Application Due Date: November 02, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: The purpose of this Notice of Funding Opportunity (NOFO) is to encourage clinical research that will advance understanding of how substance use disorder (SUD) relevant cognitive, emotional, and social processes are modulated by Psychedelics. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving psychedelics. This NOFO uses a R61/R33 Phased Innovation award activity code to support applications that propose mechanistic studies designed to understand a behavior or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention. In addition, applications must meet the NIH definition of a clinical trial. NIH defines a clinical trial as “A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.” ([NOT-OD-15-015](#)). **Note:** For basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants” please use the companion NOFO - Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Studies with Humans (BESH) [RFA-DA-24-029](#). For projects not requiring a phased research approach, applicants are encouraged to apply under a different activity code (e.g., [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required). This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Companion Funding Opportunity: [RFA-DA-24-028](#) (R01); [RFA-DA-24-029](#) (R61/R33)

Budget: NIDA intends to commit \$1.5M in FY 2024 to fund up to 4 awards in response to this NOFO and the companion NOFOs [RFA-DA-24-028](#) and [RFA-DA-24-029](#). For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed \$700,000. For the R33 phase, budgets may not exceed \$500,000 per year and need to reflect the actual needs of the proposed project. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.

14. Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-24-028](#)

Type: R01

Application Due Date: November 02, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: This notice of funding opportunity (NOFO) will support research to improve our understanding of psychedelic drug mechanisms in the context of substance use disorders (SUDs). This NOFO will also support the design and synthesis of chemical biology tools and probes to aid basic research on psychedelics and their translational pharmacology. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered

incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available [PEDP guidance material](#).

Budget: NIDA intends to commit \$1.5M in FY 2024 to fund up to 4 awards in response to this NOFO and the companion NOFOs [RFA-DA-24-024](#) and [RFA-DA-24-029](#). Application budgets are limited to \$350,000 direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**Research Development and Support Division (RDSD) &
Grants Management Office (GMO)**
Faculty of Medicine and Health Sciences
009 Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105